- DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
- DGAP-News: MorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
- DGAP-News: MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
- DGAP-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
- DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
- DGAP-News: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
- DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
- DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022
More ▼
Key statistics
On Friday, MorphoSys AG (MOR:HAM) closed at 22.81, 37.37% above the 52 week low of 16.61 set on May 12, 2022.
52-week range
Markit short selling activity
Open | 23.06 |
---|---|
High | 23.06 |
Low | 22.81 |
Bid | -- |
Offer | -- |
Previous close | 22.81 |
Average volume | 132.73 |
---|---|
Shares outstanding | 34.23m |
Free float | 34.23m |
P/E (TTM) | -- |
Market cap | 766.80m EUR |
EPS (TTM) | -24.93 EUR |
Data delayed at least 15 minutes, as of Aug 12 2022 08:49 BST.
More ▼